Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Bioorg Med Chem Lett. 2008 Jul 18;18(22):5916–5919. doi: 10.1016/j.bmcl.2008.07.062

Figure 3.

Figure 3

MS analysis of irreversible EGFR inhibitors binding to Bmx kinase domain. MS spectra of (a) Bmx kinase domain, and the protein after addition of (b) PD168393 or (c) CI-1033 showing mass increases of 369 Da and 485 Da respectively. Tandem mass spectra of peptide ISNGCLL resulting from chymotryptic digestion of Bmx kinase domain after addition of (d) PD168393 or (e) CI-1033, confirming modification of cysteine 496.